
The FDA’s new CBER Safety Council separates post-market biologics safety review from approvals, raising oversight for cell and gene therapy developers.
To ensure the development and reliable supply of medicines to patients around the world, pharmaceutical and biotech companies increasingly rely on CDMOs, their capabilities and their output. How do you choose an outsourcing partner that will meet your high expectations, not only in the short term, but throughout the lifetime of your product? Read more





